<DOC>
	<DOCNO>NCT02863367</DOCNO>
	<brief_summary>Evaluate efficacy safety Apatinib ( 500mg/d ) gemcitabine ( 1000mg/m2 ) advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>A One-Arm Exploratory Clinical Trial Apatinib Plus Gemcitabine Patients With Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>This test single center , one-armed exploratory clinical research , aim evaluation efficacy safety Apatinib Gemcitabine patient advance metastatic pancreatic cancer . This study plan Tianjin Medical University Cancer Institute Hospital.From launch July 2016 , research intend recruit end time December 2017 , expect end test time December 2017 . If appearance follow circumstance , subject inform consent , drug toxicity tolerance researcher think fit test , subject research treatment time expect imaging tumor progression .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Age patient range 18 75 year old . 2 . Histologically cytologic confirm advanced metastatic pancreatic cancer ( Exclusion islet cell tumor ) . 3 . Must receive radiotherapy , chemotherapy experimental treatment advance metastatic pancreatic cancer . Transfer postoperative recurrence patient advance pancreatic cancer also group . 4 . Karnofsky Performance Status Scale ( KPS ) ≥70 . 5 . The first confirmed date advance metastatic pancreatic cancer 6 week start treatment . 6 . No jaundice symptom . Obviously abdominal water symptom , need drainage advance . Do n't need adjust analgesic therapy . 7 . Adequate hematologic function : Hemoglobin ( HGB ) ≥ 90g/dL , Platelets ( PLT ) ≥ 100×10^9/L , absolute number Neutrophil ( ANC ) ≥ 1.5×10^9/L . 8 . Adequate hepatic , renal , heart function : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5×the upper limit normal ( ULN ) .If liver metastasis , AST ALT ≤5.0×the ULN . Total bilirubin within ULN . Serum Creatinine within ULN , creatinine clearance ≥ 60 mL/min . 9 . Blood coagulation test result : Prothrombin Time ( PT ) Partial Thromboplastin Time ( PPT ) within ±15 % normal . 10 . No clinically significant abnormal urine analysis result . 11 . Women pregnancy lactation , fertility treatment 6 month treatment termination unwilling unable use effective contraception avoid pregnancy patient male female 12 . Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment 13 . Patient consent well compliance , schedule accept visit , treatment , laboratory test study procedure 1 . Patients know brain metastasis . 2 . Patients locally advanced disease . 3 . Decline serum albumin ( ALB ) ≥ 20 % screen visit cycle 1 day 1 prior 72 hour . 4 . Over past five year history malignant tumor ( include chronic leukemia ) . Patients carcinoma situ basal cell carcinoma squamous cell skin cancer select . 5 . With need systemic treatment activity , unable control bacterial , viral fungal infection 6 . Known HIV infection , active hepatitis B hepatitis C virus ( HCV ) infection . 7 . A major surgery ( include diagnostic surgery ) 4 week start treatment . 8 . In period 6 month start treatment , Patients myocardial infarction , severe unstable angina , coronary artery peripheral artery bypass grafting , New York heart association ( NYHA ) three four level cardiac failure , control high blood pressure , Patients clinical significance arrhythmia abnormal electrocardiogram ( ECG ) , cerebrovascular accident , transient ischemic attack , epilepsy , clinical significance arrhythmia history abnormal electrocardiogram ( ECG ) . 9 . Has study drug accessory history allergy allergic reaction , patient show product control drug prescribe information `` contraindication special warning precaution '' section Outlines event . 10 . The history connective tissue disease ( lupus , scleroderma , nodular arteritis ) . 11 . Has history interstitial pneumonia , slowly progressive dyspnea cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , hypersensitivity pneumonitis , variety allergy . 12 . Could damage patient safety integrity data situation , include severe medical risk factor , medical event laboratory abnormality mental illness ; 13 . Enter clinical study , involve drug test , may interfere study program evaluation ; 14 . The patient willing meet research program , plan vacation research treatment 7 day seven day ; 15 . The investigator think person n't fit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>